FDA's No-Bid Contracts Could Be Further Reduced, Even With Recent Progress
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency now awarding 80 percent of eligible contracts competitively.
You may also be interested in...
FDA To Review Contractor Workforce In Broad Staffing Assessment
Agency's budgeting and prioritization efforts are more difficult because it does not know how much it spends on contractors, GAO notes.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.